An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders

Saeed Shojaee, Kofi Asare-Addo, Waseem Kaialy, Ali Nokhodchi, Iain Cumming

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Matrices containing PEO fail to provide stable drug release profiles when stored at elevated temperatures for a period of time. The present study aims to stabilize diltiazem HCl release from matrices made from various molecular weights of polyox powders. To this end, various molecular weights of polyox with and without vitamin E (0.25, 0.5 and 1% w/w) were stored at 40 C for 0, 2, 4 and 8 weeks. The aged polyox powders were then mixed with the model drug at a ratio of 1:1 and compressed into tablets. At different time intervals, the aged polyox with vitamin E were taken out of oven and mixed with the drug (1:1 ratio) and compressed into tablets. Dissolution studies showed a significant increase in diltiazem HCl release rate to occur with increased storage time at 40 C ± 1 from tablets made from the aged polyox (no vitamin E). This was as a result of depolymerization of the aged polyox powders as compared to the fresh polyox samples. This was confirmed by differential scanning calorimetry (DSC) which showed a reduction in the melting point of the aged samples. Concentrations of vitamin E as low as 0.25% w/w was able to overcome the quick release of drug from the matrices made from aged polyox powders. DSC traces showed that the melting point of aged polyox samples containing vitamin E remained the same as that of the fresh samples. The presence of vitamin E is essential to stabilize the drug release from polyox matrices containing diltiazem HCl.

Original languageEnglish
Pages (from-to)1190-1198
Number of pages9
JournalAAPS PharmSciTech
Volume14
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Diltiazem
Vitamin E
Powders
Tablets
Differential Scanning Calorimetry
Freezing
Molecular Weight
Pharmaceutical Preparations
Temperature
Drug Liberation

Cite this

Shojaee, Saeed ; Asare-Addo, Kofi ; Kaialy, Waseem ; Nokhodchi, Ali ; Cumming, Iain. / An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders. In: AAPS PharmSciTech. 2013 ; Vol. 14, No. 3. pp. 1190-1198.
@article{6554edeca6d04a63aefc1a03c2d1dbfc,
title = "An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders",
abstract = "Matrices containing PEO fail to provide stable drug release profiles when stored at elevated temperatures for a period of time. The present study aims to stabilize diltiazem HCl release from matrices made from various molecular weights of polyox powders. To this end, various molecular weights of polyox with and without vitamin E (0.25, 0.5 and 1{\%} w/w) were stored at 40 C for 0, 2, 4 and 8 weeks. The aged polyox powders were then mixed with the model drug at a ratio of 1:1 and compressed into tablets. At different time intervals, the aged polyox with vitamin E were taken out of oven and mixed with the drug (1:1 ratio) and compressed into tablets. Dissolution studies showed a significant increase in diltiazem HCl release rate to occur with increased storage time at 40 C ± 1 from tablets made from the aged polyox (no vitamin E). This was as a result of depolymerization of the aged polyox powders as compared to the fresh polyox samples. This was confirmed by differential scanning calorimetry (DSC) which showed a reduction in the melting point of the aged samples. Concentrations of vitamin E as low as 0.25{\%} w/w was able to overcome the quick release of drug from the matrices made from aged polyox powders. DSC traces showed that the melting point of aged polyox samples containing vitamin E remained the same as that of the fresh samples. The presence of vitamin E is essential to stabilize the drug release from polyox matrices containing diltiazem HCl.",
keywords = "depolymerization, drug release kinetics, molecular weight, polyox matrices, thermal behaviour",
author = "Saeed Shojaee and Kofi Asare-Addo and Waseem Kaialy and Ali Nokhodchi and Iain Cumming",
year = "2013",
month = "9",
doi = "10.1208/s12249-013-0013-7",
language = "English",
volume = "14",
pages = "1190--1198",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "3",

}

An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders. / Shojaee, Saeed; Asare-Addo, Kofi; Kaialy, Waseem; Nokhodchi, Ali; Cumming, Iain.

In: AAPS PharmSciTech, Vol. 14, No. 3, 09.2013, p. 1190-1198.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders

AU - Shojaee, Saeed

AU - Asare-Addo, Kofi

AU - Kaialy, Waseem

AU - Nokhodchi, Ali

AU - Cumming, Iain

PY - 2013/9

Y1 - 2013/9

N2 - Matrices containing PEO fail to provide stable drug release profiles when stored at elevated temperatures for a period of time. The present study aims to stabilize diltiazem HCl release from matrices made from various molecular weights of polyox powders. To this end, various molecular weights of polyox with and without vitamin E (0.25, 0.5 and 1% w/w) were stored at 40 C for 0, 2, 4 and 8 weeks. The aged polyox powders were then mixed with the model drug at a ratio of 1:1 and compressed into tablets. At different time intervals, the aged polyox with vitamin E were taken out of oven and mixed with the drug (1:1 ratio) and compressed into tablets. Dissolution studies showed a significant increase in diltiazem HCl release rate to occur with increased storage time at 40 C ± 1 from tablets made from the aged polyox (no vitamin E). This was as a result of depolymerization of the aged polyox powders as compared to the fresh polyox samples. This was confirmed by differential scanning calorimetry (DSC) which showed a reduction in the melting point of the aged samples. Concentrations of vitamin E as low as 0.25% w/w was able to overcome the quick release of drug from the matrices made from aged polyox powders. DSC traces showed that the melting point of aged polyox samples containing vitamin E remained the same as that of the fresh samples. The presence of vitamin E is essential to stabilize the drug release from polyox matrices containing diltiazem HCl.

AB - Matrices containing PEO fail to provide stable drug release profiles when stored at elevated temperatures for a period of time. The present study aims to stabilize diltiazem HCl release from matrices made from various molecular weights of polyox powders. To this end, various molecular weights of polyox with and without vitamin E (0.25, 0.5 and 1% w/w) were stored at 40 C for 0, 2, 4 and 8 weeks. The aged polyox powders were then mixed with the model drug at a ratio of 1:1 and compressed into tablets. At different time intervals, the aged polyox with vitamin E were taken out of oven and mixed with the drug (1:1 ratio) and compressed into tablets. Dissolution studies showed a significant increase in diltiazem HCl release rate to occur with increased storage time at 40 C ± 1 from tablets made from the aged polyox (no vitamin E). This was as a result of depolymerization of the aged polyox powders as compared to the fresh polyox samples. This was confirmed by differential scanning calorimetry (DSC) which showed a reduction in the melting point of the aged samples. Concentrations of vitamin E as low as 0.25% w/w was able to overcome the quick release of drug from the matrices made from aged polyox powders. DSC traces showed that the melting point of aged polyox samples containing vitamin E remained the same as that of the fresh samples. The presence of vitamin E is essential to stabilize the drug release from polyox matrices containing diltiazem HCl.

KW - depolymerization

KW - drug release kinetics

KW - molecular weight

KW - polyox matrices

KW - thermal behaviour

UR - http://www.scopus.com/inward/record.url?scp=84890143795&partnerID=8YFLogxK

U2 - 10.1208/s12249-013-0013-7

DO - 10.1208/s12249-013-0013-7

M3 - Article

VL - 14

SP - 1190

EP - 1198

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 3

ER -